BioGend Therapeutics Co., Ltd. (TPEX:6733)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
33.75
-0.20 (-0.59%)
Mar 24, 2026, 1:30 PM CST
Market Cap4.20B +0.7%
Revenue (ttm)222.34M +32.6%
Net Income-84.61M
EPS-0.69
Shares Out124.36M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume180,781
Average Volume238,357
Open34.10
Previous Close33.95
Day's Range33.60 - 34.50
52-Week Range23.20 - 49.15
Beta0.19
RSI31.33
Earnings DateFeb 26, 2026

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia. BioGend Therapeutics Co., Ltd. was fou... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6733
Full Company Profile

Financial Performance

In 2025, BioGend Therapeutics's revenue was 222.34 million, an increase of 32.62% compared to the previous year's 167.65 million. Losses were -84.61 million, -27.36% less than in 2024.

Financial Statements